Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-PNT2002 + brachytherapy
- Development stage
- Unknown
- Lead developer
- Lantheus
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Interstitial
01
Overview
177Lu-PNT2002 + brachytherapy is an investigational combination therapy being evaluated for the treatment of locally recurrent prostate cancer. The regimen consists of 177Lu-PNT2002, a radioligand therapy that targets the prostate-specific membrane antigen (PSMA), and High Dose Radiation (HDR) brachytherapy. 177Lu-PNT2002 (also known as 177Lu-PSMA-I&T) utilizes the beta-emitting radioisotope Lutetium-177 to deliver targeted radiation to PSMA-expressing cells both within the prostate and systemically. HDR brachytherapy involves the temporary placement of radioactive sources directly into the prostate to deliver a concentrated dose of radiation to the local tumor. This combination approach, studied in the ROADSTER trial led by Glenn Bauman, aims to improve local control while simultaneously addressing potential micrometastatic disease outside the prostate.
- Other names
- 177Lu-PNT2002 plus HDR brachytherapyRadioligand fOr locAl raDiorecurrent proStaTe cancERROADSTER trial regimen
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 177Lu-PNT2002 + brachytherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-PNT2002 + brachytherapy.